Evidence map›Paper›PMID 38232129›Full record

ArticlePLOS global public health2024

Iterative evaluation of mobile computer-assisted digital chest x-ray screening for TB improves efficiency, yield, and outcomes in Nigeria.

Rupert A Eneogu, Ellen M H Mitchell, Chidubem Ogbudebe, Danjuma Aboki, Victor Anyebe, Chimezie B Dimkpa, Daniel Egbule, Bassey Nsa, Emmy van der Grinten, Festus O Soyinka and 11 more

Open access · goldAbstract read
In one paragraph

Article in PLOS global public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 9 institutions in 5 countries.

Rupert A EneoguUnited States Agency for International Development (USAID), Abuja, Nigeria.
Ellen M H MitchellMycobacterial Diseases and Neglected Tropical Diseases Unit, Department of Public Health, Institute of Tropical Medicine, Antwerp, Belgium.ORCID https://orcid.org/0000-0002-2824-3499
Chidubem OgbudebeKNCV TB Foundation, Abuja, Nigeria.ORCID https://orcid.org/0000-0002-9616-0695
Danjuma AbokiNasarawa State TB and Leprosy Control Program, Nasarawa, Nigeria.
Victor AnyebeKNCV TB Foundation, Abuja, Nigeria.
Chimezie B DimkpaKNCV TB Foundation, Abuja, Nigeria.
Daniel EgbuleNasarawa State TB and Leprosy Control Program, Nasarawa, Nigeria.
Bassey NsaMcMaster University, Ontario, Canada.
Emmy van der GrintenKNCV TB Foundation, The Hague, Netherlands.
Festus O SoyinkaOgun State Ministry of Health, Ogun, Nigeria.
Hussein Abdur-RazzaqLagos State Ministry of Health, Lagos, Nigeria.
Sani UseniKNCV TB Foundation, Abuja, Nigeria.
Adebola LawansonNational TB and Leprosy Program, Federal Ministry of Health Nigeria, Abuja, Nigeria.
Simeon OnyemaechiNational TB and Leprosy Program, Federal Ministry of Health Nigeria, Abuja, Nigeria.
Emperor UbochiomaNational TB and Leprosy Program, Federal Ministry of Health Nigeria, Abuja, Nigeria.
Jerod ScholtenKNCV TB Foundation, The Hague, Netherlands.
Johan VerhoefKNCV TB Foundation, The Hague, Netherlands.
Peter NwadikeKNCV TB Foundation, The Hague, Netherlands.
Nkemdilim ChukwuemeNew York Medical College, New York, NY, United States of America.
Debby NongoUnited States Agency for International Development (USAID), Abuja, Nigeria.
Mustapha GidadoKNCV TB Foundation, The Hague, Netherlands.
TuBerculosis Vaccine Initiative · NLCaritas Nigeria · NGFederal Ministry of Health · NGNasarawa State University · NGUnited States Agency for International Development · USInstituut voor Tropische Geneeskunde · BEMcMaster University · CANew York Medical College · USOgun State Ministry of Health

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Wellness on Wheels (WoW) is a model of mobile systematic tuberculosis (TB) screening of high-risk populations combining digital chest radiography with computer-aided automated detection (CAD) and chronic cough screening to identify presumptive TB clients in communities, health facilities, and prisons in Nigeria. The model evolves to address technical, political, and sustainability challenges. Screening methods were iteratively refined to balance TB yield and feasibility across heterogeneous populations. Performance metrics were compared over time. Screening volumes, risk mix, number needed to screen (NNS), number needed to test (NNT), sample loss, TB treatment initiation and outcomes. Efforts to mitigate losses along the diagnostic cascade were tracked. Persons with high CAD4TB score (≥80), who tested negative on a single spot GeneXpert were followed-up to assess TB status at six months. An experimental calibration method achieved a viable CAD threshold for testing. High risk groups and key stakeholders were engaged. Operations evolved in real time to fix problems. Incremental improvements in mean client volumes (128 to 140/day), target group inclusion (92% to 93%), on-site testing (84% to 86%), TB treatment initiation (87% to 91%), and TB treatment success (71% to 85%) were recorded. Attention to those as highest risk boosted efficiency (the NNT declined from 8.2 ± SD8.2 to 7.6 ± SD7.7). Clinical diagnosis was added after follow-up among those with ≥ 80 CAD scores and initially spot -sputum negative found 11 additional TB cases (6.3%) after 121 person-years of follow-up. Iterative adaptation in response to performance metrics foster feasible, acceptable, and efficient TB case-finding in Nigeria. High CAD scores can identify subclinical TB and those at risk of progression to bacteriologically-confirmed TB disease in the near term.

Identifiers

PMID38232129
PMCPMC10793917
OpenAlexW4390938734

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.